Document Zbj6b05XLKw5BdvJx8DgL91J

To: From: Cc: Bcc: Received Date: Subject: Methvin, Stacy P SCC-DCA <lO=SHELLlOU=MSXSCC/CN=RECIPIENTS/CN=USSME4>; Williams, Charlie CR SIEP-EPT-RL <lO=SHELLlOU=MSXSEPC/CN=RECI PI ENTS/CN=CW188045 >; Simpson, Edward J SCC-DCAl2 <lO=SHELLlOU=MSXSCC/CN=RECI PI ENTS/CN=USESIO> Clegg, Patsy M SCC-DCS/22 <lO=SHELLlOU=MSXSCC/CN=RECIPIENTS/CN=PH197432> Snyder, Phil J SDIUS-DXXl9 <lO=SHELLlOU=MSXSCC/CN=RECIPIENTS/CN=PS193987>; Sykes, Paul B SCC-DCS/23 <lO=SHELLlOU=MSXSCC/CN=RECI PI ENTS/CN=USPSYO>; Williams, Elizabeth J SCAI-DCS/22 <lO=SHELLlOU=MSXSCC/CN=RECI PI ENTS/CN=CEBWI1 >; Cagen, Stuart Z SHLOIL-SHOIL-SHS <lO=SHELLlOU=MSXSCC/CN=RECI PI ENTS/CN=SC724012>; Tsai, Shan P SHLOIL-SHS <lO=SHELLlOU=MSXSOC/CN=RECI PI ENTS/CN=ST196949>; Semmler, Klaus K DSC-DCS/235 <lO=SHELLlOU=OPC/CN=RECIPI ENTS/CN=HAKSE1> 2007-04-1721 :48:55 GMT Shanghai Health Study Update Progress is being made towards establishing a new contract with CinPathogen and extending the University of Colorado grant to support finishing the Shanghai Health Study. Key issues include providing advance funding to keep the lab operating while new contracts are being established and developing specific deliverables and timelines for the new contract and grant. All sponsors have executed contract amendment 4 agreeing to additional funding. Timeline for the study: June 30 07 December 31 07 (formerly NHL) case accrual 2008 publications will continue beyond 08) December 31 08 disbands End AML case accrual End lymphoid neoplasms Data analysis and publications (some Study ends; consortium Key events are listed below. April 11: API Executive Committee reached consensus on (1) supporting the advance of $800K to Dr. Irons providing that he agrees to certain terms. No additional funds until contract is in place. Attached is the letter that Red Cavaney sent to Dr. Irons. 41107_RCLettertoR Irons.pdf (43 ... (2) fun ing through CinPathogen conditional on all API contract criteria being met. The draft list of action items from the meeting: SH ELL-MCCLU RG-058954 ~~ Action Items - draft.ZIP (6 KB... April 16: Dr. Irons signed letter. API wired $aDDK to CinPathogen. Irons isgned letter on April 12; IT challenges in transmitting to API. Consortium conference call to further develop list of deliverables to support items in Irons/APlletter. API has discussed with Irons, so understanding and agreement can be more quickly achieved. April 26 Consortium call scheduled to finalize deliverables and get up update on API contracting criteria being met. I will keep you updated. Happy to address any questions or comments. Patsy Clegg Product Steward Shell Chem ical LP One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916 Tel: +1 713241 2521 Fax: 3325 Email: patsy.clegg@shell.com Internet: http://www.shell.com/chemicals Attachments: 41107_RCLettertoRI rons. pdf Action Items - draft.ZIP SH ELL-MCCLU RG-058955 Shanghai Health Study - Conference call Friday, April 13 at 4 PM EDTFrom: Howard Feldman [Feldman@api.org] Sent: Friday, April 13, 2007 8:48 AM To: BenzConsort-OC@listserve.api.org; BenzConsort-TC@listserve.api.org; BHRC Communications Committee; myron.c.harrison@exxonmobil.com; Snyder, Phil J SDIUS-DXX/9; Bob Greco; Brenda Hargett; Harry Ng Subject: RE: Shanghai Health Study - Conference call Friday, April 13 at 4 PM EDT BHRC, In advance of today's call, the draft follow-up List of Actions flowing from Wednesday's API Executive Committee call is listed below. (The final list may be slightly modified based on comments received from the Executive Committee.) 1. API will work with the SHS Oversight Committee chair to identify acceptance conditions for an advance payment to Cinpathogen, Inc. (Cinpathogen) to maintain the operational capabilities of the research program. Those conditions will include: 1) itemization of the "how" and over what time period the $800,000 advance payment is to be spent, 2) identification of progress milestones to be achieved in the second quarter, 2007, and 3) delineation of deliverables and milestones to be utilized in potential development of a contract with Cinpathogen. These conditions will be forwarded ASAP to Dr. Richard Irons for his acceptance. 2. Upon acceptance, and affirmation electronically to API, of those conditions by Dr. Irons, API will then wire $800,000 to Cinpathogen. 3. As part of API's ongoing due diligence, API and the Oversight Committee will examine 1) Cinpathogen's incorporation papers, business plan and related financial statements and banking relationships, and other items as needed to best assess the company's viability, 2) the Cinpathogen proposal and any subsequent revisions thereof, and 3) any underlying agreements and contracts that Cinpathogen has established, or intends to establish, to complete this study. API will ensure that any final proposal includes tying study payments to metrics of progress towards study completion to occur no later than year end 2008. SH ELL-MCCLU RG-058956 4. The study will terminate at the end of 2008. 5. The API General Committee on Special Programs will be asked to play an active role in overseeing the SHS program to ensure its timely completion by year end 2008. 6. API, working with the Oversight Committee, will provide the Executive Committee with a risk/benefit analysis of contracting with Cinpathogen (a for-profit entity) to complete a substantial portion of the remainder of this study, as opposed to a study under the auspices of a not-for-profit organization. 7. API, working with the Oversight Committee, will provide the Executive Committee with a risk/benefit analysis for the Benzene Health Research Consortium continuing as an API Special Program with API continuing to serve as its program administrator, and a companion risk/benefit analysis of the consortium acting apart from API as a separate entity for the remainder of the program. Howard Feldman From: Russell White [mailto:whiter@api.org] Sent: Thursday, April 12, 2007 9: 16 AM To: BenzConsort-OC@listserve.api.org; BenzConsort-TC@listserve.api.org; BHRC Communications Committee; myron.c.harrison@exxonmobil.com; phil.snyder@shell.com Subject: Shanghai Health Study - Conference call Friday, April 13 at 4 PM EDT A conference call has been scheduled for Friday, April 13 at 4 PM EDT to discuss the Shanghai Health Study. Draft Agenda 1) Establish quorum and notetaker - Patsy 2) Antitrust reminder - Mark 3) Update on API Executive Committee call - Howard 4) Update on call with Otto Wong - Jennifer SH ELL-MCCLU RG-058957 5) Update on Cinpathogen contract proposal - Russ 6) Other issues - All 7) Next meeting or call - Patsy Conference call: Toll Free Dial-In Number: (866) 443-0059 International Dial-In: (770) 765-9147 Enter this code at the prompt: 202 682 8344# Operator-Assisted Service: Toll-Free Dial-In Number: (800) 572-9844 International Dial-In Number: (706) 643-1733 Call Participant Functions *0 Operator assistance *6 Mute your own line Russell White Regulatory and Scientific Affairs American Petroleum Institute 1220 L Street NW Washington, DC 20005-4070 Tel: 202-682-8344 Fax: 202-682-8270 SH ELL-MCCLU RG-058958